References
DISEASE PROGRESSION
Study design.Disease progression status after 18 months of PectaSolThe number of patients in each PSADT risk group at baseline and after 18 months of PectaSolPre-treatment (baseline) patient characteristics.Treatment characteristics and responses after 18 months of PectaSol